A Phase 3 interventional study of insulin degludec/insulin aspart and biphasic insulin aspart in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 32 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-11.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 45th largest by enrollment, is one of 6 that started in 2016, is one of 49 in phase 3, and was the 47th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 263 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 192nd largest by enrollment of the 428 interventional ones that give a count, is one of 20 that started in 2016, is one of 187 in phase 3, and was the 409th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Africa and Asia. The aim of this trial is to compare efficacy and safety of insulin degludec/insulin aspart twice daily and biphasic insulin aspart twice daily in subjects with type 2 diabetes mellitus before, during and after Ramadan.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 263 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec/insulin aspart
Drug: biphasic insulin aspart
Drug pages: Insulin degludec · Insulin Aspart
Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
Change in HbA1c (%) (Glycosylated Haemoglobin)
Mean change in HbA1c was evaluated from baseline (week 0) to end of Ramadan (day 29 of Ramadan).
Time frame: From week 0 to end of Ramadan (day 29 of Ramadan)
Change in Fasting Plasma Glucose (FPG)
Mean change in FPG was evaluated from baseline (week 0) to end of Ramadan (day 29 of Ramadan).
Time frame: From week 0 to end of Ramadan (day 29 of Ramadan)
Change in Fructosamine
Mean change in fructosamine was evaluated from baseline (week 0) to end of Ramadan (day 29 of Ramadan).
Time frame: From week 0 to end of Ramadan (day 29 of Ramadan)
Number of Subjects Who Achieve HbA1c Below 7% (53 mmol/Mol (American Diabetes Association (ADA) Target )
Number of subjects who achieved HbA1c below 7% (53 mmol/mol; ADA target) at the end of Ramadan (day 29 of Ramadan).
Time frame: End of Ramadan (day 29 of Ramadan)
Number of Subjects Who Achieve FPG Below or Equal to 7.2 mmol/L (ADA Target)
Number of subjects who achieved FPG \<=7.2 mmol/L at the end of Ramadan (day 29 of Ramadan). The above written (in the endpoint title) 'ADA target' is not applicable for FPG.
Time frame: End of Ramadan (day 29 of Ramadan)
Number of Treatment Emergent Hypoglycaemic Episodes Both According to the Novo Nordisk Definition for Hypoglycaemic Episodes (Severe or BG Hypoglycaemia) as Well as According to the ADA definition1 Confirmed Symptomatic
Treatment-emergent hypoglycaemic episodes: If the onset of the episode occurred on or after the first day of investigational medicinal product (IMP; IDegAsp/BIAsp 30) administration, and no later than 1 day after the last day on IMP, before switching to or being treated with another insulin product. The above mentioned definitions (in endpoint title) should read as the following: Novo Nordisk definition; severe or blood glucose (BG) confirmed symptomatic hypoglycaemia: An episode that was severe according to ADA classification or BG confirmed by a plasma glucose (PG) value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. American Diabetes Association (ADA) definition; documented symptomatic hypoglycaemia: An episode, during which typical symptoms of hypoglycaemia were accompanied by a measured PG concentration ≤3.9 mmol/L (70 mg/dL). Due to character limitation, severe hypoglycaemia as per ADA classification is not defined here; see next outcome measure.
Time frame: From week 0 to 4 weeks post Ramadan
Number of Treatment Emergent Nocturnal (00:01-05:59 am) Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes, which occurred between 00:01 and 05:59 both inclusive. Novo Nordisk definition; severe or blood glucose (BG) confirmed symptomatic hypoglycaemia: An episode that was severe according to ADA classification or BG confirmed by a plasma glucose (PG) value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia as per ADA classification: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
Time frame: From week 0 to 4 weeks post Ramadan
The trial was conducted at 27 sites in 5 countries as follows: Algeria: 4 sites; India: 7 sites; Lebanon: 4 sites; Malaysia: 3 sites; South Africa: 9 sites.
| Milestone | Insulin Degludec/Insulin Aspart | Biphasic Insulin Aspart 30 |
|---|---|---|
| Started | 131 | 132 |
| Exposed | 130 | 132 |
| Completed | 121 | 127 |
| Not completed | 10 | 5 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Withdrawal by subject | 4 | 3 |
| Withdrew: Unclassified | 5 | 0 |
Mean change in HbA1c was evaluated from baseline (week 0) to end of Ramadan (day 29 of Ramadan).
| Percentage (%) of HbA1c | Insulin Degludec/Insulin Aspart | Biphasic Insulin Aspart 30 |
|---|---|---|
| Change in HbA1c (%) (Glycosylated Haemoglobin) | -1.11 ± 0.13 | -1.13 ± 0.13 |
Mean change in FPG was evaluated from baseline (week 0) to end of Ramadan (day 29 of Ramadan).
| mmol/L | Insulin Degludec/Insulin Aspart | Biphasic Insulin Aspart 30 |
|---|---|---|
| Change in Fasting Plasma Glucose (FPG) | -2.0 ± 12.4 | -4.4 ± 18.0 |
Mean change in fructosamine was evaluated from baseline (week 0) to end of Ramadan (day 29 of Ramadan).
| mmol/L | Insulin Degludec/Insulin Aspart | Biphasic Insulin Aspart 30 |
|---|---|---|
| Change in Fructosamine | -0.035 ± 0.051 | -0.035 ± 0.048 |
Number of subjects who achieved HbA1c below 7% (53 mmol/mol; ADA target) at the end of Ramadan (day 29 of Ramadan).
| Number of subjects | Insulin Degludec/Insulin Aspart | Biphasic Insulin Aspart 30 |
|---|---|---|
| Subjects with HbA1c <7.0% (Yes) | 38 | 42 |
| Subjects with HbA1c <7.0% (No) | 83 | 81 |
Number of subjects who achieved FPG \<=7.2 mmol/L at the end of Ramadan (day 29 of Ramadan). The above written (in the endpoint title) 'ADA target' is not applicable for FPG.
| Number of subjects. | Insulin Degludec/Insulin Aspart | Biphasic Insulin Aspart 30 |
|---|---|---|
| Subjects with FPG <=7.2 mmol/L (Yes) | 65 | 83 |
| Subjects with FPG <=7.2 mmol/L (No) | 56 | 40 |
Treatment-emergent hypoglycaemic episodes: If the onset of the episode occurred on or after the first day of investigational medicinal product (IMP; IDegAsp/BIAsp 30) administration, and no later than 1 day after the last day on IMP, before switching to or being treated with another insulin product. The above mentioned definitions (in endpoint title) should read as the following: Novo Nordisk definition; severe or blood glucose (BG) confirmed symptomatic hypoglycaemia: An episode that was severe according to ADA classification or BG confirmed by a plasma glucose (PG) value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. American Diabetes Association (ADA) definition; documented symptomatic hypoglycaemia: An episode, during which typical symptoms of hypoglycaemia were accompanied by a measured PG concentration ≤3.9 mmol/L (70 mg/dL). Due to character limitation, severe hypoglycaemia as per ADA classification is not defined here; see next outcome measure.
| Number of episodes. | Insulin Degludec/Insulin Aspart | Biphasic Insulin Aspart 30 |
|---|---|---|
| Severe or BG confirmed symptomatic hypoglycaemia | 93 | 389 |
| Documented symptomatic hypoglycaemia | 521 | 775 |
Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes, which occurred between 00:01 and 05:59 both inclusive. Novo Nordisk definition; severe or blood glucose (BG) confirmed symptomatic hypoglycaemia: An episode that was severe according to ADA classification or BG confirmed by a plasma glucose (PG) value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia as per ADA classification: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
| Number of episodes. | Insulin Degludec/Insulin Aspart | Biphasic Insulin Aspart 30 |
|---|---|---|
| Number of Treatment Emergent Nocturnal (00:01-05:59 am) Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes | 18 | 106 |
Collected over From first day of exposure to randomised treatment (week 0) and no later than seven days after the last day of randomised treatment (i.e., after 16-28 weeks; 8-20 weeks treatment initiation period [pre-Ramadan], 4-week Ramadan treatment period, and 4 week post-Ramadan period).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin Degludec/Insulin Aspart | — | 5/130 (3.8%) | 54/130 (41.5%) |
| Biphasic Insulin Aspart 30 | — | 3/132 (2.3%) | 47/132 (35.6%) |
| Event | Insulin Degludec/Insulin Aspart | Biphasic Insulin Aspart 30 |
|---|---|---|
| Myocardial infarctionCardiac disorders | 2/130 | 0/132 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/130 | 2/132 |
| Endometrial adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/130 | 0/132 |
| FallInjury, poisoning and procedural complications | 1/130 | 0/132 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/130 | 0/132 |
| Lumbar spinal stenosisMusculoskeletal and connective tissue disorders | 1/130 | 0/132 |
| PneumoniaInfections and infestations | 1/130 | 0/132 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 1/130 | 0/132 |
| Umbilical herniaGastrointestinal disorders | 1/130 | 0/132 |
| Accidental overdoseInjury, poisoning and procedural complications | 0/130 | 1/132 |
| Event | Insulin Degludec/Insulin Aspart | Biphasic Insulin Aspart 30 |
|---|---|---|
| Blood glucose decreasedInvestigations | 46/130 | 40/132 |
| Upper respiratory tract infectionInfections and infestations | 8/130 | 3/132 |
| PyrexiaGeneral disorders | 4/130 | 7/132 |
Baseline results are based on the full analysis set (FAS), which included all randomised subjects.
| Age, Continuous(Years) | Insulin Degludec/Insulin Aspart | Biphasic Insulin Aspart 30 | Total |
|---|---|---|---|
| Mean | 54.9 ± 9.8 | 55.3 ± 9.2 | 55.1 ± 9.5 |
| Sex: Female, Male(Participants) | Insulin Degludec/Insulin Aspart | Biphasic Insulin Aspart 30 | Total |
|---|---|---|---|
| Female | 67 | 80 | 147 |
| Male | 64 | 52 | 116 |
| Glycated haemoglobin (HbA1c)(Percentage of HbA1c) | Insulin Degludec/Insulin Aspart | Biphasic Insulin Aspart 30 | Total |
|---|---|---|---|
| Mean | 8.5 ± 0.9 | 8.5 ± 0.9 | 8.5 ± 0.9 |
| Fasting plasma glucose (FPG)(mmol/L) | Insulin Degludec/Insulin Aspart | Biphasic Insulin Aspart 30 | Total |
|---|---|---|---|
| Mean | 9.9 ± 10.4 | 10.6 ± 16.3 | 10.3 ± 13.6 |
Ran from Jan 2016 to primary completion in Sep 2016, 8 months.
Results were first posted in Sep 2018, 2 years after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 8 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Insulin Aspart